POLIO
MCID: PLM031
MIFTS: 63

Poliomyelitis (POLIO)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 74 20 58 44 15 17 71
Infantile Paralysis 20 71
Polio 20 54

Characteristics:

Orphanet epidemiological data:

58
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases


Summaries for Poliomyelitis

GARD : 20 Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. It is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. There are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. Symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. Treatment is aimed at controlling symptoms while the infection runs its course. Since the development of the polio vaccine, the incidence of the disease has been greatly reduced. The prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected.

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to nonparalytic poliomyelitis and paralytic poliomyelitis. An important gene associated with Poliomyelitis is PVR (PVR Cell Adhesion Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Calcium carbonate and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skeletal muscle and skin, and related phenotypes are vomiting and fatigue

Disease Ontology : 12 A viral infectious disease that results in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted by ingestion of food or water contaminated with feces, or transmitted by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 74 Poliomyelitis, commonly shortened to polio, is an infectious disease caused by the poliovirus. In about... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 848)
# Related Disease Score Top Affiliating Genes
1 nonparalytic poliomyelitis 32.5 PI4KB EIF4G1
2 paralytic poliomyelitis 32.4 PVR EIF4G1 CD4 BTK
3 tetanus 31.5 TNF IL4 IL10 IFNG
4 aseptic meningitis 31.0 TNF IL10 IFNG
5 smallpox 31.0 TNF IL4 IFNG ICAM1
6 mumps 30.9 TNF IL10 IFNG
7 rubella 30.9 TNF IL4 IL10 IFNG
8 meningitis 30.8 TNF IL4 IL10 IFNG ICAM1 FCGR2A
9 variola major 30.8 CD8A CD4
10 neuritis 30.7 TNF IL4 IL10 IFNG
11 myocarditis 30.7 TNF IL4 IL10 IFNG ICAM1
12 respiratory failure 30.5 TNF IL10 ICAM1 CD8A CD4
13 osteomyelitis 30.3 TNF IL4 IL10 IFNG
14 meningoencephalitis 30.3 TNF IL10 CD8A CD4
15 graft-versus-host disease 30.3 TNF IL10 IFNG
16 sleep apnea 30.3 TNF LEP IL10 ICAM1
17 disease by infectious agent 30.2 TNF IL4 IL10 IFNG FCGR2A CD8A
18 cerebral palsy 30.2 TNF LEP IL4 IL10
19 penicillin allergy 30.2 IL4 IL10 IFNG
20 viral encephalitis 30.2 TNF IL10 CD8A CD4
21 myasthenia gravis 30.2 TNF IL4 IL10 IFNG FCGR2A
22 spondylitis 30.1 TNF IL10 IFNG
23 bacterial meningitis 30.1 TNF IL10 IFNG
24 conjunctivitis 30.1 TNF IL4 IL10 IFNG ICAM1 BTK
25 pulmonary edema 30.1 TNF IL10 ICAM1
26 fibromyalgia 30.1 TNF LEP IL10
27 brucellosis 30.1 TNF IL4 IL10 IFNG
28 chronic fatigue syndrome 30.1 TNF IL4 IL10 IFNG
29 human immunodeficiency virus type 1 30.1 TNF IL10 IFNG FCGR3B CD4
30 severe acute respiratory syndrome 30.1 TNF IL10 IFNG
31 common variable immunodeficiency 30.1 TNF IL4 IL10 IFNG BTK
32 acquired immunodeficiency syndrome 30.1 TNF IL10 IFNG ICAM1 FCGR3A CD4
33 rheumatic fever 30.0 TNF IL10 IFNG ICAM1 FCGR2A
34 arteriosclerosis 30.0 IL4 IL10 IFNG ICAM1
35 dermatitis herpetiformis 30.0 TNF IL4 IL10
36 hepatitis a 30.0 TNF IL4 IL10 IFNG CD4
37 scrub typhus 30.0 TNF IL10 IFNG
38 pyelonephritis 30.0 TNF IL10 IFNG
39 appendicitis 30.0 TNF IL10 IFNG
40 trichinosis 29.9 IL4 IL10 CD4
41 pericarditis 29.9 TNF LEP IFNG
42 reactive arthritis 29.9 TNF IL10 IFNG
43 acute myocarditis 29.9 TNF IL10 CD4
44 diarrhea 29.9 TNF LEP IL10 IFNG
45 chlamydia 29.9 TNF IL4 IL10 IFNG
46 schistosomiasis 29.9 TNF IL4 IL10 IFNG
47 hand, foot and mouth disease 29.9 SCARB2 IL10 IFNG
48 endocarditis 29.9 TNF IL10 IFNG FCGR2A
49 exanthem 29.9 TNF IL10 IFNG CD8A CD4
50 tonsillitis 29.9 TNF IL4 IL10 IFNG

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

Human phenotypes related to Poliomyelitis:

58 31 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vomiting 58 31 frequent (33%) Frequent (79-30%) HP:0002013
2 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 skeletal muscle atrophy 58 31 frequent (33%) Frequent (79-30%) HP:0003202
5 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
6 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
7 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
8 areflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001284
9 meningitis 58 31 frequent (33%) Frequent (79-30%) HP:0001287
10 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
11 paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0003470
12 muscle flaccidity 58 31 frequent (33%) Frequent (79-30%) HP:0010547
13 hypoplasia of the musculature 58 31 frequent (33%) Frequent (79-30%) HP:0009004
14 brisk reflexes 58 31 frequent (33%) Frequent (79-30%) HP:0001348
15 lower limb muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0007340
16 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
17 nausea 58 31 frequent (33%) Frequent (79-30%) HP:0002018
18 myelitis 58 31 frequent (33%) Frequent (79-30%) HP:0012486
19 stiff neck 58 31 frequent (33%) Frequent (79-30%) HP:0025258
20 abnormal motor nerve conduction velocity 58 31 frequent (33%) Frequent (79-30%) HP:0040131
21 pharyngitis 58 31 frequent (33%) Frequent (79-30%) HP:0025439
22 low self esteem 58 31 frequent (33%) Frequent (79-30%) HP:0031469
23 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
24 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
25 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
26 immunodeficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0002721
27 bulbar signs 58 31 occasional (7.5%) Occasional (29-5%) HP:0002483
28 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
29 fasciculations 58 31 occasional (7.5%) Occasional (29-5%) HP:0002380
30 respiratory failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002878
31 respiratory failure requiring assisted ventilation 58 31 occasional (7.5%) Occasional (29-5%) HP:0004887
32 inability to walk 58 31 occasional (7.5%) Occasional (29-5%) HP:0002540
33 paraparesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002385
34 upper limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003484
35 bulbar palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0001283
36 fatigable weakness of respiratory muscles 58 31 occasional (7.5%) Occasional (29-5%) HP:0030196
37 hyperkinetic movements 58 31 occasional (7.5%) Occasional (29-5%) HP:0002487
38 absent tonsils 58 31 occasional (7.5%) Occasional (29-5%) HP:0030813
39 diminished movement 58 31 occasional (7.5%) Occasional (29-5%) HP:0002374
40 impairment of activities of daily living 58 31 occasional (7.5%) Occasional (29-5%) HP:0031058
41 paralytic ileus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002590
42 hypotension 58 31 very rare (1%) Very rare (<4-1%) HP:0002615
43 hypertension 58 31 very rare (1%) Very rare (<4-1%) HP:0000822
44 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
45 irritability 58 31 very rare (1%) Very rare (<4-1%) HP:0000737
46 coma 58 31 very rare (1%) Very rare (<4-1%) HP:0001259
47 confusion 58 31 very rare (1%) Very rare (<4-1%) HP:0001289
48 agitation 58 31 very rare (1%) Very rare (<4-1%) HP:0000713
49 hypovolemic shock 58 31 very rare (1%) Very rare (<4-1%) HP:0031274
50 muscle weakness 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Poliomyelitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 ATG7 BTK CD4 CD8A DLG1 FCGR2A
2 digestive/alimentary MP:0005381 10.1 ATG7 BTK CD4 DLG1 ICAM1 IFNG
3 immune system MP:0005387 10.1 ATG7 BTK CD4 CD8A DLG1 FCGR2A
4 endocrine/exocrine gland MP:0005379 10.07 ATG7 CD4 CD8A DLG1 ICAM1 IFNG
5 integument MP:0010771 9.85 ATG7 BTK CD4 CD8A ICAM1 IFNG
6 neoplasm MP:0002006 9.5 ATG7 BTK ICAM1 IFNG IL10 LEP
7 no phenotypic analysis MP:0003012 9.23 CD4 DLG1 EIF4G1 FCGR3B IFNG IL10

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
4
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
5
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
6
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
7
Pentetic acid Approved Phase 4 67-43-6
8
Iron Approved Phase 4 7439-89-6 23925 29936
9
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
10 Antibodies, Blocking Phase 4
11 Immunologic Factors Phase 4
12 Trace Elements Phase 4
13 Acidophilus Phase 4
14 Zinc Supplement Phase 4
15 Calcium, Dietary Phase 4
16 Nutrients Phase 4
17 Micronutrients Phase 4
18 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
19 Immunoglobulins Phase 4
20 Antibodies Phase 4
21 Polymyxins Phase 4
22 Protective Agents Phase 4
23 Iron Chelating Agents Phase 4
24 Chelating Agents Phase 4
25 Antidotes Phase 4
26 PENTA Phase 4
27 Fibrinolytic Agents Phase 4
28 Anticoagulants Phase 4
29
Calcium Nutraceutical Phase 4 7440-70-2 271
30
Lactitol Approved, Investigational Phase 3 585-86-4 157355
31
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
32 Vaccines Phase 3
33 taxane Phase 3
34 Hemagglutinins Phase 3
35 Somatomedin B Phase 3
36 gamma-Globulins Phase 2, Phase 3
37 Immunoglobulins, Intravenous Phase 2, Phase 3
38 Rho(D) Immune Globulin Phase 2, Phase 3
39 Pharmaceutical Solutions Phase 3
40 Neuroprotective Agents Phase 3
41 Central Nervous System Stimulants Phase 3
42
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
43
Phenol Approved, Experimental Phase 2 108-95-2 996
44
Racepinephrine Approved Phase 2 329-65-7 838
45
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
46
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
47 Epinephryl borate Phase 2
48 Cola Phase 2
49
Glycine Approved, Nutraceutical, Vet_approved Phase 1 56-40-6 750
50 Autoantibodies Phase 1

Interventional clinical trials:

(show top 50) (show all 241)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
2 To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan Unknown status NCT01908114 Phase 4
3 Intestinal and Humoral Immunity of Monovalent Oral Poliovirus Vaccine Type 1 When Administered With and Without Fractional Inactivated Poliovirus Vaccine Unknown status NCT03722004 Phase 4
4 A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children Unknown status NCT03460002 Phase 4
5 Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan Unknown status NCT03286803 Phase 4
6 Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh Completed NCT02412514 Phase 4
7 Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants Completed NCT01616693 Phase 4
8 Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants. Completed NCT01695798 Phase 4
9 A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation Completed NCT01094171 Phase 4
10 Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh Completed NCT02643368 Phase 4
11 A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs) Completed NCT01831050 Phase 4
12 Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone. Completed NCT01475539 Phase 4
13 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic Completed NCT02580201 Phase 4
14 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
15 A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants Completed NCT02521974 Phase 4
16 Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study Completed NCT01244464 Phase 4
17 Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
18 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
19 A Study of Immunogenicity and Seroconversion With Sabin Inactivated Polio Vaccine Schedules in China. Completed NCT03597919 Phase 4
20 Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study Completed NCT01278433 Phase 4
21 Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination Completed NCT01323959 Phase 4
22 Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
23 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
24 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
25 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Completed NCT03147560 Phase 4
26 a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine Completed NCT04051736 Phase 4
27 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
28 Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04224519 Phase 4
29 Phase IV Safety Monitoring Study of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Completed NCT04220515 Phase 4
30 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
31 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
32 Sero-conversion Study for a Two-dose Schedule of Sabin Strain Inactivated Poliovirus Vaccine in China Completed NCT03546634 Phase 4
33 A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
34 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
35 Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines Completed NCT02847026 Phase 4
36 Duration of Priming and Antibody Decay With Full-dose Inactivated Poliovirus Vaccine (IPV) Administered With or Without Bivalent Oral Poliovirus Vaccine (bOPV) Completed NCT03202719 Phase 4
37 Cross-sectional Study to Assess Persistence of Immunity Conferred by a Single IPV Dose Administered in the Expanded Program on Immunization(EPI) Routine Immunization Schedule Completed NCT03723837 Phase 4
38 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
39 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
40 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
41 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
42 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
43 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
44 Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age Completed NCT01457547 Phase 4
45 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
46 Immunogenicity of Intramuscular and Intradermal Inactivated Poliovirus Vaccine in Routine Immunization Recruiting NCT04063150 Phase 4
47 Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV Recruiting NCT03890497 Phase 4
48 Randomised, Double-blinded, Open Label Study in Pregnant Women, Exploring the Impact of Acellular Pertussis Vaccination in Pregnancy on the Immunogenicity in Infants Randomized to Receive Either an Acellular (aP) or Whole Cell Pertussis (wP) Vaccine Subsequently Recruiting NCT03606096 Phase 4
49 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) Recruiting NCT04636827 Phase 4
50 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Recruiting NCT04638985 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

40
Spinal Cord, Skeletal Muscle, Skin, Bone Marrow, Bone, Eye, Endothelial

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 20843)
# Title Authors PMID Year
1
Stable isotope labeling by amino acids in cell culture and differential plasma membrane proteome quantitation identify new substrates for the MARCH9 transmembrane E3 ligase. 54 61
19457934 2009
2
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis. 61 54
18317803 2008
3
Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. 54 61
17517601 2007
4
Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. 61 54
16336935 2005
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21. 61 54
15033568 2004
6
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. 54 61
14654644 2003
7
Tissue-specific replicating capacity of a chimeric poliovirus that carries the internal ribosome entry site of hepatitis C virus in a new mouse model transgenic for the human poliovirus receptor. 61 54
12970433 2003
8
Establishment of European Pharmacopoeia BRP batch 2 for inactivated poliomyelitis vaccine for in vitro D antigen assay. 61 54
14563307 2003
9
The neuropathology observed in wild-type mice inoculated with human poliovirus mirrors human paralytic poliomyelitis. 54 61
12220986 2002
10
Recent insights into poliovirus pathogenesis. 54 61
11597452 2001
11
Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. 54 61
10777530 2000
12
Expression of the poliovirus receptor in intestinal epithelial cells is not sufficient to permit poliovirus replication in the mouse gut. 61 54
9188553 1997
13
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. 61 54
9203668 1997
14
Identification of two determinants that attenuate vaccine-related type 2 poliovirus. 61 54
1847458 1991
15
Prior poliomyelitis-reduced capillary supply and metabolic enzyme content in hypertrophic slow-twitch (type I) muscle fibres. 54 61
2030351 1991
16
Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. 54 61
2170026 1990
17
Protective immune responses against Haemophilus influenza type b elicited by a fully-liquid DTaP-IPV-Hib-HepB vaccine (VAXELIS™). 61
33541794 2021
18
Prevalence and Effect of Obesity on Mobility According to Different Criteria in Polio Survivors. 61
33595937 2021
19
Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. 61
33487470 2021
20
The association between the density of vaccination workers and immunization coverage in Zhejiang province, East China. 61
33545020 2021
21
The Risk of Resurgence in Vaccine Preventable Infections Due to COVID-Related Gaps in Immunization. 61
33580243 2021
22
Anti-poliovirus activity of Nerium oleander aqueous extract. 61
30908090 2021
23
Prevalence of posttraumatic stress disorder after infectious disease pandemics in the twenty-first century, including COVID-19: a meta-analysis and systematic review. 61
33542468 2021
24
A critical assessment of proposed outbreaks of plague and other epidemic diseases in Ancient Egypt. 61
33227516 2021
25
Disease Surveillance Investments and Administration: Limits to Information Value in Pakistan Polio Eradication. 61
32822075 2021
26
Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029. 61
33590519 2021
27
High Diversity of Human Non-Polio Enterovirus Serotypes Identified in Contaminated Water in Nigeria. 61
33562806 2021
28
Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. 61
31960533 2021
29
An Updated Economic Analysis of the Global Polio Eradication Initiative. 61
33590521 2021
30
Seroprevalence of poliovirus antibodies before and after polio vaccine switch in 2012 and 2017 in Beijing. 61
32703060 2021
31
The challenges of insecurity on implementing vaccination campaign and its effect on measles elimination and control efforts: A case study of 2017/18 measles campaign in Borno state, Nigeria. 61
33546886 2021
32
Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. 61
32144841 2021
33
Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria. 61
32348634 2021
34
Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. 61
32632925 2021
35
Modeling and Managing Poliovirus Risks: We are Where we are…. 61
33590520 2021
36
Molecular detection of cosaviruses in a patient with acute flaccid paralysis and in sewage samples in Germany. 61
33548413 2021
37
Seroprevalence of hepatitis B virus infection markers among children in Ukraine, 2017. 61
33583671 2021
38
Vaccine-Derived Polioviruses, Central African Republic, 2019. 61
33496226 2021
39
Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. 61
32936466 2021
40
Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. 61
32339327 2021
41
Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. 61
33174263 2021
42
Potential Future Use, Costs, and Value of Poliovirus Vaccines. 61
32645244 2021
43
Neurological issues during severe COVID-19 in a tertiary level hospital in Western India. 61
33592305 2021
44
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. 61
33084153 2021
45
[Expert consensus on informed consent for vaccination (part one)]. 61
33548950 2021
46
[Expert consensus on informed consent for vaccination(Part One)]. 61
33548951 2021
47
The role of 3'UTR of RNA viruses on mRNA stability and translation enhancement. 61
33596798 2021
48
Urban-rural differences in factors associated with incomplete basic immunization among children in Indonesia: A nationwide multilevel study. 61
32962954 2021
49
Incomplete vaccination and associated factors among children aged 12-23 months in South Africa: an analysis of the South African demographic and health survey 2016. 61
32703070 2021
50
Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. 61
32573398 2021

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TNF PVR IL4 IL10 IFNG ICAM1
2
Show member pathways
13.51 TNF IL4 IL10 IFNG ICAM1 EIF4G1
3
Show member pathways
13.33 TNF IL4 IL10 IFNG ICAM1 EIF4G1
4
Show member pathways
12.78 TNF IL4 IL10 IFNG ICAM1 EIF4G1
5
Show member pathways
12.64 TNF IL4 IL10 IFNG CD4 BTK
6
Show member pathways
12.6 TNF IL4 IL10 IFNG DLG1 CD8A
7
Show member pathways
12.59 TNF IL4 IL10 IFNG CD4
8
Show member pathways
12.54 TNF IL4 IFNG ICAM1 FCGR3B FCGR3A
9 12.54 TNF PVR IL4 IL10 IFNG CD8A
10
Show member pathways
12.38 LEP IL4 IL10 IFNG
11 12.31 TNF ICAM1 DLG1 CD4
12
Show member pathways
12.3 TNF IL4 IFNG ICAM1
13 12.23 TNF IL10 IFNG FCGR3B FCGR3A FCGR2A
14
Show member pathways
12.14 TNF IL4 IL10 IFNG FCGR3B FCGR3A
15 12.12 PVR ICAM1 CD8A CD4
16 12.1 TNF IL10 FCGR2A CD8A CD4
17 12.07 PVR ICAM1 FCGR3A CD8A
18 11.99 TNF IL4 IL10 ICAM1
19 11.99 TNF IFNG FCGR3B FCGR3A FCGR2A BTK
20
Show member pathways
11.98 IL4 IFNG CD8A CD4
21 11.92 TNF LEP IL4 IFNG ICAM1 FCGR2A
22 11.91 TNF IL4 CD8A CD4
23 11.9 IL10 ICAM1 FCGR3B FCGR3A FCGR2A
24
Show member pathways
11.78 TNF IL10 IFNG CD4
25 11.77 IL4 IFNG ICAM1
26
Show member pathways
11.73 TNF IL4 IFNG
27 11.72 TNF IL10 IFNG CD8A CD4
28
Show member pathways
11.64 TNF IFNG ICAM1
29 11.64 TNF IL4 IL10 IFNG CD8A CD4
30
Show member pathways
11.62 TNF IFNG CD8A
31 11.58 TNF IL10 IFNG ICAM1
32 11.57 TNF IL4 IL10 ICAM1
33 11.56 TNF IL4 IL10 IFNG FCGR2A CD8A
34 11.52 IL4 IL10 IFNG CD4
35 11.41 TNF IL10 IFNG ICAM1
36 11.4 CD8A CD4 BTK
37
Show member pathways
11.37 TNF IL10 IFNG
38 11.31 TNF IL4 IFNG
39 11.21 IL4 IL10 IFNG
40 11.02 TNF IL4 IL10 IFNG CD4
41 10.99 TNF IL4 IL10 ICAM1 FCGR3B FCGR3A

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF PVR LEP IL4 IL10 IFNG
2 external side of plasma membrane GO:0009897 9.55 TNF ICAM1 FCGR3A CD8A CD4
3 membrane raft GO:0045121 9.02 TNF ICAM1 DLG1 CD4 BTK

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.95 TNF IL4 IL10 ICAM1 CD4
2 viral process GO:0016032 9.95 SCARB2 PVR PI4KB ICAM1 EIF4G1 DLG1
3 positive regulation of protein phosphorylation GO:0001934 9.92 TNF LEP IFNG CD4
4 cell surface receptor signaling pathway GO:0007166 9.85 IFNG FCGR3B FCGR3A FCGR2A CD8A CD4
5 response to insulin GO:0032868 9.82 LEP IL10 ICAM1
6 regulation of insulin secretion GO:0050796 9.82 TNF LEP IFNG
7 positive regulation of T cell proliferation GO:0042102 9.8 LEP IL4 CD4
8 positive regulation of protein localization to plasma membrane GO:1903078 9.79 TNF IFNG DLG1
9 negative regulation of autophagy GO:0010507 9.77 LEP IL10 EIF4G1
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.74 TNF IFNG ICAM1
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.73 IL4 IL10 ICAM1
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF LEP IL4 IFNG
13 positive regulation of JAK-STAT cascade GO:0046427 9.69 TNF LEP IL10
14 microglial cell activation GO:0001774 9.67 TNF IL4 IFNG
15 negative regulation of amyloid-beta clearance GO:1900222 9.65 TNF IFNG
16 negative regulation of lipid storage GO:0010888 9.64 TNF LEP
17 endothelial cell apoptotic process GO:0072577 9.63 TNF IL10
18 positive regulation of cytokine production GO:0001819 9.62 TNF LEP IL10 IFNG
19 positive regulation of mononuclear cell migration GO:0071677 9.61 TNF IL4
20 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
21 positive regulation of cellular respiration GO:1901857 9.59 IL4 IFNG
22 neuroinflammatory response GO:0150076 9.58 IL4 IFNG
23 type 2 immune response GO:0042092 9.58 IL4 IL10
24 immune response GO:0006955 9.56 TNF IL4 IL10 IFNG FCGR3B FCGR3A
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 TNF IFNG
26 regulation of isotype switching GO:0045191 9.52 IL4 IL10
27 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
28 positive regulation of nitrogen compound metabolic process GO:0051173 9.46 TNF IFNG
29 T cell activation GO:0042110 9.46 IL4 DLG1 CD8A CD4
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IL4 IL10 IFNG
31 regulation of immune response GO:0050776 9.17 PVR IL4 ICAM1 FCGR3B FCGR3A FCGR2A

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL4 IL10 IFNG
2 virus receptor activity GO:0001618 9.46 SCARB2 PVR ICAM1 CD4
3 IgG binding GO:0019864 9.13 FCGR3B FCGR3A FCGR2A
4 transmembrane signaling receptor activity GO:0004888 9.1 SCARB2 ICAM1 FCGR3B FCGR3A FCGR2A CD4

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....